|
Research
Front Name
|
Percentage of corporate affiliations
|
Leading
corporation
|
|
METABOLITE IDENTIFICATION; EARLY DRUG DISCOVERY USING
HIGH-RESOLUTION LIQUID CHROMATOGRAPHY/QUADRUPOLE
TIME-OF-FLIGHT MASS SPECTROMETRY
|
41
|
Waters Corp
|
|
TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND
RECEPTOR ACTIVATING AGENTS; FULLY HUMAN TRAIL-RECEPTOR
1 MONOCLONAL ANTIBODY; MAPATUMUMAB
|
35
|
Genentech Inc
|
|
HEPATITIS C VIRUS SERINE PROTEASE INHIBITOR; HEPATITIS
C VIRUS NS3-4A SERINE PROTEASE; NOVEL HEPATITIS C VIRUS
PRO-TEASE INHIBITOR
|
29
|
Boehringer Ingelheim Pharmaceut Inc
|
|
AURORA KINASE INHIBITOR VX-680; POTENT AURORA KINASE
ACTIVITY; MULTITARGETED KINASE INHIBITOR; NOVEL KINASE
INHIBITOR
|
29
|
Vertex Pharmaceuticals Inc
|
|
HUMAN PROTEIN INTERACTIONS; GENE MENTION FINDING
EVALUATION; BIOCREATIVE TASKS; BIOMEDICAL TEXT MINING
|
26
|
Mitre Corp
|
|
TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED;
TYPE 2
DIABETES FAILING THIAZOLIDINEDIONE MONOTHERAPY
|
26
|
Amylin Pharmaceuticals Inc
|
|
HIGHLY EFFICIENT ENDOGENOUS HUMAN GENE CORRECTION USING
DESIGNED ZINC-FINGER NUCLEASES; GENOME EDITING USING
ZINC-FINGER NUCLEASES
|
24
|
Sangamo BioSciences Inc
|
|
MOLECULAR DOCKING ACCURACY; VIRTUAL SCREENING USING
PROTEIN-LIGAND DOCKING; MOLECULAR DOCKING USING
POLYNOMIAL EMPIRICAL SCORING FUNCTIONS
|
24
|
Schrodinger LLC
|
|
STENT THROMBOSIS FOLLOWING PERCUTANEOUS CORONARY
INTERVENTION; ACUTE CORONARY SYNDROME PATIENTS
RECEIVING CORONARY STENTING
|
20
|
Eli Lilly and Co
|
